Medicare Enrolled
Dr. Diana Superfin, M.D.
Hematology & Oncology · Walnut Creek, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Superfin from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Superfin?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Superfin
Dr. Diana Superfin is a hematology & oncology specialist in Walnut Creek, CA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Superfin performed 103,032 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Superfin received a total of $48,715 from 100 pharmaceutical and/or device companies across 1594 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Superfin is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years of NPI registration
▲ Top 7% volume in CA
$48,715 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗103,032
Medicare services
Top 7% in CA for hematology & oncology
Not available
Unique patients (not deduplicated)
$9
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
34,500 | $1 | $3 |
| Iron infusion (Feraheme) An injection of ferumoxytol used to treat iron deficiency anemia in patients not on dialysis. |
16,830 | $0 | $2 |
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
16,600 | $2 | $10 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
12,750 | $0 | $5 |
| Denosumab injection (Prolia/Xgeva) | 7,020 | $19 | $50 |
| Contrast dye for imaging (iodine-based) A contrast agent containing 300-399 mg/ml of iodine used to enhance imaging studies. It is administered per milliliter to improve the visibility of internal structures. |
4,200 | $0 | $1 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
2,734 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,450 | $1 | $5 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
1,092 | $160 | $310 |
| Pegfilgrastim injection, 0.5 mg An injection of pegfilgrastim, a medication that stimulates the production of white blood cells. This specific code applies to the brand-name drug and excludes biosimilar versions. |
972 | $89 | $400 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
646 | $2 | $10 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
613 | $118 | $230 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
525 | $16 | $75 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
353 | $14 | $50 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
322 | $141 | $400 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
225 | $66 | $175 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
204 | $6 | $20 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
184 | $29 | $150 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
166 | $30 | $75 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
160 | $1 | $3 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 137 | $288 | $600 |
| Nuclear medicine scan from skull base to mid-thigh with CT A nuclear medicine imaging study covering the area from the base of the skull to the middle of the thighs, performed alongside a CT scan. |
130 | $1,641 | $3,500 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
130 | $69 | $250 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
127 | $1 | $5 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
98 | $108 | $220 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
83 | $1 | $40 |
| New patient office visit, complex (60-74 min) | 82 | $201 | $500 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
80 | $21 | $100 |
| On-body injector for subcutaneous injection A device is applied to the skin to automatically deliver a medication injection under the skin. |
80 | $19 | $50 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
67 | $40 | $125 |
| Injection, hydrocortisone sodium succinate, up to 100 mg | 65 | $14 | $30 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
50 | $58 | $150 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
48 | $25 | $50 |
| Flu vaccine, high-dose High-dose seasonal influenza vaccine for adults aged 65 and older. Contains four times the antigen of standard-dose flu vaccines (60 mcg per strain), split-virus formulation, preservative-free, single-dose syringe. |
42 | $72 | $80 |
| Flu vaccine administration This procedure involves the administration of the influenza virus vaccine. It covers the process of delivering the vaccine to the patient. |
42 | $37 | $40 |
| Prolonged office E/M service, first 15 minutes This code is used for additional time spent by a physician beyond the maximum required time of a primary office or outpatient evaluation and management service. It is billed in 15-minute increments based on total time spent on the date of the primary service. |
42 | $30 | $220 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
37 | $157 | $500 |
| CT scan of abdomen and pelvis with contrast A CT scan that uses dye to create detailed images of the abdomen and pelvis. This imaging test helps doctors examine internal organs and structures in these areas. |
34 | $222 | $600 |
| CT scan of chest with contrast A computed tomography scan of the chest using a contrast dye to enhance the visibility of internal structures. |
29 | $111 | $609 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
27 | $35 | $175 |
| CT scan of chest, without contrast A computed tomography scan of the chest area that uses X-rays to create detailed images without the use of contrast dye. |
22 | $83 | $500 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
18 | $82 | $154 |
| Telephone medical discussion, 21-30 minutes A telephone conversation with a physician lasting between 21 and 30 minutes. This code covers the time spent discussing medical matters over the phone. |
16 | $41 | $80 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
50.7% high complexity
47.0% medium
2.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$48,715
Total received (2018-2024)
Avg $6,959/year across 7 years
Top 12% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
100
Companies
1,594
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$7,536
2023
$7,300
2022
$7,062
2021
$3,570
2020
$3,613
2019
$6,825
2018
$12,809
Payments by company (2024)
AstraZeneca Pharmaceuticals LP
$3,104
PFIZER INC.
$710
Novartis Pharmaceuticals Corporation
$278
GlaxoSmithKline, LLC.
$256
Daiichi Sankyo Inc.
$228
E.R. Squibb & Sons, L.L.C.
$228
Celgene Corporation
$226
Janssen Biotech, Inc.
$222
Merck Sharp & Dohme LLC
$206
ABBVIE INC.
$158
Lilly USA, LLC
$128
SpringWorks Therapeutics, Inc.
$126
Astellas Pharma US Inc
$104
Takeda Pharmaceuticals U.S.A., Inc.
$100
EMD Serono, Inc.
$95
BeiGene USA, Inc.
$79
GENZYME CORPORATION
$76
Genentech USA, Inc.
$76
Eisai Inc.
$71
Gilead Sciences, Inc.
$66
Spectrum Pharmaceuticals Inc.
$62
Immunocore Limited
$62
JAZZ PHARMACEUTICALS INC.
$62
PUMA BIOTECHNOLOGY, INC.
$59
Kyowa Kirin, Inc.
$57
Deciphera Pharmaceuticals Inc.
$55
Stemline Therapeutics Inc.
$51
Regeneron Healthcare Solutions, Inc.
$50
TerSera Therapeutics LLC
$41
Fresenius Kabi USA, LLC
$39
Boehringer Ingelheim Pharmaceuticals, Inc.
$39
SUN PHARMACEUTICAL INDUSTRIES INC.
$38
Alexion Pharmaceuticals, Inc.
$34
Coherus Biosciences Inc.
$29
Amgen Inc.
$28
SOBI, INC
$28
Genmab U.S., Inc.
$26
TAIHO ONCOLOGY, INC.
$26
Exelixis Inc.
$24
Pharmacosmos Therapeutics Inc.
$24
Ipsen Biopharmaceuticals, Inc
$23
SERVIER PHARMACEUTICALS LLC
$23
Kite Pharma, Inc.
$23
RECORDATI_RARE_DISEASES_INC.
$21
Aveo Pharmaceuticals, Inc.
$21
ARRAY BIOPHARMA INC
$20
Incyte Corporation
$17
ADC Therapeutics America, Inc.
$15
Top 3 companies account for 54.3% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$6,341
Puma Biotechnology, Inc.
$4,711
TESARO, Inc.
$4,125
Kite Pharma, Inc.
$3,736
Janssen Biotech, Inc.
$3,066
Takeda Pharmaceuticals U.S.A., Inc.
$2,453
PFIZER INC.
$1,861
E.R. Squibb & Sons, L.L.C.
$1,411
Astellas Pharma US Inc
$1,399
Celgene Corporation
$1,313
Novartis Pharmaceuticals Corporation
$1,195
Amgen Inc.
$1,105
GlaxoSmithKline, LLC.
$1,017
Genentech USA, Inc.
$958
Seagen Inc.
$784
GENZYME CORPORATION
$738
Daiichi Sankyo Inc.
$710
Lilly USA, LLC
$701
Pharmacyclics LLC, An AbbVie Company
$673
Merck Sharp & Dohme Corporation
$571
TerSera Therapeutics LLC
$552
Incyte Corporation
$421
Eisai Inc.
$393
Octapharma USA, Inc.
$392
Bayer HealthCare Pharmaceuticals Inc.
$356
Myovant Sciences Inc.
$314
Merck Sharp & Dohme LLC
$313
Exelixis Inc.
$308
Gilead Sciences, Inc.
$279
Foundation Medicine, Inc.
$268
Clovis Oncology, Inc.
$255
Alexion Pharmaceuticals, Inc.
$240
Stemline Therapeutics Inc.
$236
BeiGene USA, Inc.
$234
Regeneron Healthcare Solutions, Inc.
$220
PUMA BIOTECHNOLOGY, INC.
$218
EMD Serono, Inc.
$199
EISAI INC.
$199
Agios Pharmaceuticals, Inc.
$194
Karyopharm Therapeutics Inc.
$183
ABBVIE INC.
$180
Sumitomo Pharma America, Inc.
$171
Epizyme, Inc.,
$166
Array BioPharma Inc.
$152
Boehringer Ingelheim Pharmaceuticals, Inc.
$146
Dendreon Pharmaceuticals LLC
$138
JAZZ PHARMACEUTICALS INC.
$127
SpringWorks Therapeutics, Inc.
$126
Spectrum Pharmaceuticals Inc.
$126
Kyowa Kirin, Inc.
$123
Jazz Pharmaceuticals Inc.
$112
Seattle Genetics, Inc.
$110
AbbVie Inc.
$110
SERVIER PHARMACEUTICALS LLC
$100
Lexicon Pharmaceuticals, Inc.
$98
SOBI, INC
$93
AVEO Pharmaceuticals, Inc.
$93
Blueprint Medicines Corporation
$93
Ipsen Biopharmaceuticals, Inc
$90
ARRAY BIOPHARMA INC
$89
Heron Therapeutics, Inc.
$84
AbbVie, Inc.
$79
Rigel Pharmaceuticals, Inc.
$76
Deciphera Pharmaceuticals Inc.
$75
Bayer Healthcare Pharmaceuticals Inc.
$74
Pharmacyclics LLC, an AbbVie Company
$71
Advanced Accelerator Applications
$64
Immunocore Limited
$62
Aurobindo Pharma USA, Inc.
$61
Janssen Pharmaceuticals, Inc
$55
Sirtex Medical Inc
$54
Genmab U.S., Inc.
$53
Acrotech Biopharma LLC
$53
Pharmacosmos Therapeutics Inc.
$52
Fresenius Kabi USA, LLC
$52
Mirati Therapeutics, Inc.
$47
Helsinn Therapeutics (U.S.), Inc.
$43
Global Blood Therapeutics, Inc.
$43
TAIHO ONCOLOGY, INC.
$39
SUN PHARMACEUTICAL INDUSTRIES INC.
$38
Mylan Institutional Inc.
$37
MorphoSys, US Inc.
$35
Taiho Oncology, Inc.
$33
PharmaEssentia USA Corporation
$30
Coherus Biosciences Inc.
$29
Adaptive Biotechnologies Corporation
$28
Sandoz Inc.
$24
Secura Bio, Inc.
$24
AMAG Pharmaceuticals, Inc.
$22
Dova Pharmaceuticals
$22
Galvanize Therapeutics, Inc
$21
RECORDATI_RARE_DISEASES_INC.
$21
Aveo Pharmaceuticals, Inc.
$21
Shire North American Group Inc
$19
Apellis Pharmaceuticals, Inc.
$18
Servier Pharmaceuticals LLC
$18
ADC Therapeutics America, Inc.
$15
Fortovia Therapeutics, Inc.
$13
Amneal Pharmaceuticals LLC
$13
INSYS Therapeutics Inc
$12
Top 3 companies account for 31.2% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · AKYNZEO · ALIMTA · ALIYA SYSTEM · ALUNBRIG · ASPARLAS · AVASTIN · AYVAKIT · Abraxane · Alecensa · Aliqopa · Aranesp · Avastin · BALVERSA · BAVENCIO · BELEODAQ · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · Beleodaq · Braftovi · CABOMETYX · CALQUENCE · CARVYKTI · CERDELGA · CINVANTI · COSELA · CYRAMZA · Cabometyx · Columvi · DARZALEX · Doptelet · ELIQUIS · ELITEK · ELREXFIO · ELZONRIS · EMPLICITI · ENHERTU · EPKINLY · ERBITUX · ERLEADA · EVENITY · Enhertu · Epkinly · Erleada · FARESTON · FARYDAK · FERAHEME · FOLOTYN · FOTIVDA · FOUNDATIONONE · FOUNDATIONONE HEME · Fabhalta · Farydak · Folotyn · Fulphila · GAVRETO · GAZYVA · GILOTRIF · HEMADY · Halaven · IBRANCE · ICLUSIG · IDHIFA · IMBRUVICA · IMFINZI · IMLYGIC · INFLECTRA · INJECTAFER · INLYTA · INREBIC · Imbruvica · JADENU · JAKAFI · JAYPIRCA · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KIMMTRAK · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LIBTAYO CEMIPLIMAB-RWLC INJECTION · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LUTATHERA (lutetium Lu 177 dotatate) · LYNPARZA · Lenvima · Lonsurf · Lutathera · MEKINIST · MONJUVI · MONOFERRIC · MYLOTARG · NERLYNX · NINLARO · Nerlynx · Neulasta · Nplate · Nubeqa · OGSIVEO · OJJAARA · ONCASPAR · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · Odomzo · Onivyde · Orserdu · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · POLIVY · POTELIGEO · PROMACTA · PROVENGE · Padcev · Perjeta · Pomalyst · Poteligeo · Prolia · QINLOCK · QTERN · QUZYTTIR · Quzyttir · REBLOZYL · RETEVMO · ROLVEDON · ROZLYTREK · RYBREVANT · RYDAPT · Revlimid · Rituxan · Rubraca · SANDOSTATIN · SARCLISA · SIR-Spheres Microspheres · SOLIRIS · SOMATULINE DEPOT · SPRYCEL · SUSTOL · SUTENT · SYLVANT · SYNDROS · Soltamox · Stimufend · Stivarga · TABRECTA · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TECVAYLI · TIBSOVO · TIVDAK · TUKYSA · TUMOR LYSIS SYNDROME - DISEASE · Tavalisse · Tecentriq · Tibsovo · Trodelvy · ULTOMIRIS · Udenyca · Ultomiris · VARUBI · VENCLEXTA · VERZENIO · VONJO · VONVENDI · VOTRIENT · VYXEOS · Venclexta · Vitrakvi · WILATE · WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · XALKORI · XARELTO · XGEVA · XOSPATA · XPOVIO · XTANDI · Xermelo · Xofigo · Xospata · Xtandi · YONSA · Yescarta · ZEJULA · ZEPZELCA · ZIEXTENZO · ZOLADEX · ZYTIGA · Zevalin · Zoladex · Zydelig · clonoSEQ
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Hematology & oncology specialists in nearby ZIP areas
103
County median income
$125,727
Nearest hospital to ZIP centroid (approximate)
JOHN MUIR MEDICAL CENTER - WALNUT CREEK CAMPUS
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Superfin is a mixed practice specialist, with above-average Medicare volume (top 7% in CA), with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Superfin experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Superfin performed 34,500 iron infusion (injectafer) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Superfin receive payments from pharmaceutical companies?
Yes. Dr. Superfin received a total of $48,715 from 100 companies across 1,594 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Superfin's costs compare to other hematology & oncology specialists in Walnut Creek?
Dr. Superfin's average Medicare payment per service is $9. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Superfin) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Walnut Creek
Browse hematology & oncology specialists in Walnut Creek ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Puma Biotechnology, Inc. Payments to Doctors
See all physicians who received payments from Puma Biotechnology, Inc.
By company
TESARO, Inc. Payments to Doctors
See all physicians who received payments from TESARO, Inc.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology